Gupta S, Wilson T, Maclean P, Rehm B, Heiser A, Buddle B
Front Immunol. 2023; 13:1087015.
PMID: 36741398
PMC: 9889921.
DOI: 10.3389/fimmu.2022.1087015.
Baruah N, Ahamad N, Halder P, Koley H, Katti D
J Nanobiotechnology. 2023; 21(1):34.
PMID: 36710326
PMC: 9884485.
DOI: 10.1186/s12951-023-01780-y.
Jimenez-Cabello L, Utrilla-Trigo S, Barreiro-Pineiro N, Pose-Boirazian T, Martinez-Costas J, Marin-Lopez A
Vaccines (Basel). 2022; 10(7).
PMID: 35891288
PMC: 9319458.
DOI: 10.3390/vaccines10071124.
Tang J, Cai L, Xu C, Sun S, Liu Y, Rosenecker J
Nanomaterials (Basel). 2022; 12(2).
PMID: 35055244
PMC: 8777913.
DOI: 10.3390/nano12020226.
Huda M, Nurunnabi M
Pharm Res. 2022; 39(11):2635-2671.
PMID: 35028802
PMC: 8757927.
DOI: 10.1007/s11095-021-03143-4.
Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.
Cai T, Liu H, Zhang S, Hu J, Zhang L
J Nanobiotechnology. 2021; 19(1):389.
PMID: 34823541
PMC: 8620195.
DOI: 10.1186/s12951-021-01146-2.
Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens.
Johnson-Weaver B, Choi H, Yang H, Granek J, Chan C, Abraham S
Front Immunol. 2021; 12:730346.
PMID: 34566991
PMC: 8461742.
DOI: 10.3389/fimmu.2021.730346.
Bacterial Outer Membrane Vesicles as a Versatile Tool in Vaccine Research and the Fight against Antimicrobial Resistance.
Zhu Z, Antenucci F, Villumsen K, Bojesen A
mBio. 2021; 12(4):e0170721.
PMID: 34372691
PMC: 8406158.
DOI: 10.1128/mBio.01707-21.
Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.
Genito C, Batty C, Bachelder E, Ainslie K
Adv Nanobiomed Res. 2021; 1(3):2000041.
PMID: 33681864
PMC: 7917382.
DOI: 10.1002/anbr.202000041.
Impact of Excipients on Stability of Polymer Microparticles for Autoimmune Therapy.
Gosselin E, Noshin M, Black S, Jewell C
Front Bioeng Biotechnol. 2021; 8:609577.
PMID: 33644005
PMC: 7906284.
DOI: 10.3389/fbioe.2020.609577.
A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention.
Machhi J, Shahjin F, Das S, Patel M, Abdelmoaty M, Cohen J
J Neuroimmune Pharmacol. 2021; 16(2):270-288.
PMID: 33544324
PMC: 7862527.
DOI: 10.1007/s11481-020-09981-0.
Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead.
de Souza G, Rocha R, Goncalves R, Ferreira C, de Mello Silva B, Froes Goulart de Castro R
Pathogens. 2021; 10(1).
PMID: 33466440
PMC: 7824877.
DOI: 10.3390/pathogens10010036.
Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic.
Di Natale C, La Manna S, De Benedictis I, Brandi P, Marasco D
Front Pharmacol. 2020; 11:578382.
PMID: 33343349
PMC: 7744882.
DOI: 10.3389/fphar.2020.578382.
Self-assembled particulate vaccine elicits strong immune responses and reduces Mycobacterium avium subsp. paratuberculosis infection in mice.
Gupta S, Parlane N, Luo D, Rehm B, Heiser A, Buddle B
Sci Rep. 2020; 10(1):22289.
PMID: 33339863
PMC: 7749150.
DOI: 10.1038/s41598-020-79407-7.
Soil-Transmitted Helminth Vaccines: Are We Getting Closer?.
Zawawi A, Else K
Front Immunol. 2020; 11:576748.
PMID: 33133094
PMC: 7565266.
DOI: 10.3389/fimmu.2020.576748.
Small and dangerous? Potential toxicity mechanisms of common exposure particles and nanoparticles.
Hewitt R, Chappell H, Powell J
Curr Opin Toxicol. 2020; 19:93-98.
PMID: 32566804
PMC: 7305026.
DOI: 10.1016/j.cotox.2020.01.006.
[Use of lactic acid bacteria as mucosal vaccines].
Bermudez-Humaran L, Langella P
Rev Francoph Lab. 2020; 2009(417):79-89.
PMID: 32518601
PMC: 7270964.
DOI: 10.1016/S1773-035X(09)70312-0.
Microfluidics as tool to prepare size-tunable PLGA nanoparticles with high curcumin encapsulation for efficient mucus penetration.
Lababidi N, Sigal V, Koenneke A, Schwarzkopf K, Manz A, Schneider M
Beilstein J Nanotechnol. 2019; 10:2280-2293.
PMID: 31807413
PMC: 6880834.
DOI: 10.3762/bjnano.10.220.
Mucosal Vaccination via the Respiratory Tract.
Hellfritzsch M, Scherliess R
Pharmaceutics. 2019; 11(8).
PMID: 31374959
PMC: 6723941.
DOI: 10.3390/pharmaceutics11080375.
Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization.
Carvalho A, Miquel-Clopes A, Wegmann U, Jones E, Stentz R, Telatin A
Clin Exp Immunol. 2019; 196(3):287-304.
PMID: 30985006
PMC: 6514708.
DOI: 10.1111/cei.13301.